RxDoctor Payments Data

Michael Kesselring, NP

Nurse Practitioner · Fairlawn, OHNPI 1033518543

Payments from drug & device makers

$4,893in general payments, 2019–2025

Across 205 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$964
  • Otsuka America Pharmaceutical, Inc.$647
  • Supernus Pharmaceuticals, Inc.$558
  • Axsome Therapeutics, Inc.$241
  • Teva Pharmaceuticals USA, Inc.$155
  • plus $144 from 2 others

What the payments were for

  • Food & beverage$4,888100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,893 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$17,185
Medicare patients
46
Services billed
210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate30$261,065
VraylarCariprazine Hcl86$123,075
RexultiBrexpiprazole23$37,996
Seroquel XrQuetiapine Fumarate37$22,881
TrintellixVortioxetine Hydrobromide33$18,060
ZubsolvBuprenorphine Hcl/Naloxone Hcl17$10,390
Aripiprazole92$8,766
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl65$8,243
VyvanseLisdexamfetamine Dimesylate21$8,039
Lamotrigine651$5,741
Bupropion XlBupropion Hcl328$5,584
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine154$5,098
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine27$3,658
XanaxAlprazolam12$3,536
Ziprasidone Hcl38$3,480

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$964$261,06530 claims
AbbVieVraylar$2,184$123,07586 claims
Otsuka America Pharmaceutical, Inc.Rexulti$647$37,99623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Fairlawn

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →